Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial)

Journal: J Acquir Immune Defic Syndr

Volume: 

Issue: 

Year of Publication: 2023

Affiliated Institutions: 

Abstract summary 

Authors & Co-authors: 

Study Outcome 

Source Link: Visit source

Statistics
Citations :  2
Authors :  0
Identifiers
Doi : 10.1097/QAI.0000000000003273
SSN : 
Study Population
Male,Female
Mesh Terms
Other Terms
Study Design
Study Approach
Country of Study
Cameroon
Publication Country